New blood markers detection technology: A leap in the diagnosis of gastric cancer
Open Access
- 1 January 2016
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (3), 1202-1212
- https://doi.org/10.3748/wjg.v22.i3.1202
Abstract
Gastric cancer (GC) is still one of the malignant tumors with high morbidity and mortality in the world, with a 5-year survival rate of less than 30%. GC is often either asymptomatic or causes only nonspecific symptoms in its early stages, whereas when the symptoms manifest, the cancer has usually reached an advanced stage, which is one of the main causes of its relatively poor prognosis. Hence, the main focus of GC research has been on discovering new tools and technology to predict, screen and diagnose GC at an early stage which would prompt early treatment. With the tremendous advances in the OMICS technology, serum proteomics has been in the limelight of cancer research over the last few decades and has steered the development of several methods helping to understand the mechanisms underlying gastric carcinogenesis, resulting in the identification of a large number of molecular targets such as circulating tumor cells (CTCs), cell free DNA (cfDNA) and cell tumor DNA (ctDNA) and their sub-molecular components such as miRNA, that show great promise as GC biomarkers. In this review, we are underlying the recent breakthroughs about new blood markers technology for GC while scrutinizing the potential clinical use of CTCs, cfDNA, ctDNA and the role of the methylation of their sub-molecular components in the pathogenesis, diagnosis and management of GC.Keywords
This publication has 72 references indexed in Scilit:
- Circulating tumor cells and DNA as liquid biopsiesGenome Medicine, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerThe New England Journal of Medicine, 2013
- Detecting Circulating Tumor Cells: Current Challenges and New TrendsTheranostics, 2013
- Identification of hsa-miR-335 as a Prognostic Signature in Gastric CancerPLOS ONE, 2012
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and ErlotinibClinical Cancer Research, 2012
- Quantitative analysis of cell-free DNA in the plasma of gastric cancer patientsOncology Letters, 2012
- A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomasBritish Journal of Cancer, 2011
- Development of Personalized Tumor Biomarkers Using Massively Parallel SequencingScience Translational Medicine, 2010
- Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancerCancer Letters, 2008
- Circulating tumour cell detection on its way to routine diagnostic implementation?European Journal of Cancer, 2007